Charles River Laboratories International, Inc. (CRL) Downgraded to Hold by CLSA

Market Context

Charles River Laboratories International, Inc. operates in the Healthcare sector. The stock currently trades at $219.70 with a market capitalization of $9.6B. The stock has gained 28.1% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow CLSA's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Charles River Laboratories International, Inc.

Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 20, 2026	CLSA	Hold	N/A
Jul 13, 2026	Mizuho	Neutral	N/A
Jul 09, 2026	Morgan Stanley	Overweight	N/A
Jun 17, 2026	Morgan Stanley	Overweight	N/A
May 29, 2026	CLSA	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View CRL Stock Page